Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RVU120 in Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
NCT04021368Phase 1Terminated
- Sponsor
- Ryvu Therapeutics
- Start
- Sep 2019
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of rvu120 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Ryvu Therapeutics. Primary endpoints: Recommended Dose up to 2 years and Incidence of Adverse Events up to 2 years. Started Sep 2019; status: terminated.
02
Drugs
rvu120
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04021368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04021368.